



Hillo: the first self-learning Artificial Intelligence for predicting blood glucose levels to obtain CE mark as a Medical Device

This Friday, January 31, 2020 Hillo officially obtained the CE mark software as a medical device for its artificial intelligence (AI) for predicting blood sugar levels in person with diabetes (PWD).

Thanks to machine learning techniques, Hillo's AI is able to evolve on its own to learn and adapt to the physiological changes specific to each patient and to changes in their habits, Hillo's AI requires only a 10 days observation and learning period.

In the diabetes digital therapeutics space, this is the first time that an AI capable of learning from its environment and evolving alone, has been validated as a medical device.

Two studies carried out with the Montpellier University Hospital and Pr. Éric Renard, have been published in international scientific congresses (ATTD, etc.) and demonstrate the performance and accuracy of the AI developed by Hillo, but also its relevance as a decision support to PWD, which allows for real time, personalized risk anticipation.

Hillo is currently working on the next versions of its AI technology, a therapeutic recommendation system to anticipate and prevent hypoglycaemia and hyperglycaemia, whose CE mark class IIB is planned for 2020, and the new generation of artificial pancreas (AP) for 2021, which will help overcome the main limitations of current AP systems thanks to the ultra-personalization provided by machine learning.

Hillo has entered into discussions with industrial partners for the integration of its solutions into existing platforms. In order to further develop its technology, the company is currently raising funds, with the help of Eponyme Partners.

Contact

Stéphane Bidet

+33 6 83 58 27 68 – presse@hillo.ai